CA2217902A1 - Use of gammahydroxybutyrric acid for the treatment of demential syndromes - Google Patents

Use of gammahydroxybutyrric acid for the treatment of demential syndromes Download PDF

Info

Publication number
CA2217902A1
CA2217902A1 CA 2217902 CA2217902A CA2217902A1 CA 2217902 A1 CA2217902 A1 CA 2217902A1 CA 2217902 CA2217902 CA 2217902 CA 2217902 A CA2217902 A CA 2217902A CA 2217902 A1 CA2217902 A1 CA 2217902A1
Authority
CA
Canada
Prior art keywords
gammahydroxybutyrric
ghb
acid
synaptic
syndromes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2217902
Other languages
English (en)
French (fr)
Inventor
Franco Beghe'
Carlo Bertoni-Freddari
Patrizia Fattoretti
Maria Teresa Carpanini
Ugo Caselli
Roberta Paoloni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratorio Farmaceutico CT SRL
Original Assignee
Laboratorio Farmaceutico CT SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorio Farmaceutico CT SRL filed Critical Laboratorio Farmaceutico CT SRL
Publication of CA2217902A1 publication Critical patent/CA2217902A1/en
Abandoned legal-status Critical Current

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA 2217902 1997-07-07 1997-10-08 Use of gammahydroxybutyrric acid for the treatment of demential syndromes Abandoned CA2217902A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT97MI001613A IT1293583B1 (it) 1997-07-07 1997-07-07 Uso dell'acido gammaidrossibutirrico per il trattamento delle sindromi demenziali
ITMI97A001613 1997-07-07

Publications (1)

Publication Number Publication Date
CA2217902A1 true CA2217902A1 (en) 1999-01-07

Family

ID=11377515

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2217902 Abandoned CA2217902A1 (en) 1997-07-07 1997-10-08 Use of gammahydroxybutyrric acid for the treatment of demential syndromes

Country Status (2)

Country Link
CA (1) CA2217902A1 (en, 2012)
IT (1) IT1293583B1 (en, 2012)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013024028A1 (en) * 2011-08-12 2013-02-21 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compounds and compositions for treating proteinopathies
US11065224B2 (en) 2016-07-22 2021-07-20 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11400065B2 (en) 2019-03-01 2022-08-02 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013024028A1 (en) * 2011-08-12 2013-02-21 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compounds and compositions for treating proteinopathies
US12115142B2 (en) 2016-07-22 2024-10-15 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11065224B2 (en) 2016-07-22 2021-07-20 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12263151B2 (en) 2016-07-22 2025-04-01 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11766418B2 (en) 2016-07-22 2023-09-26 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12263150B2 (en) 2016-07-22 2025-04-01 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11826335B2 (en) 2016-07-22 2023-11-28 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11839597B2 (en) 2016-07-22 2023-12-12 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11896572B2 (en) 2016-07-22 2024-02-13 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12097175B2 (en) 2016-07-22 2024-09-24 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12097176B2 (en) 2016-07-22 2024-09-24 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12109186B2 (en) 2016-07-22 2024-10-08 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12115143B2 (en) 2016-07-22 2024-10-15 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12257223B2 (en) 2016-07-22 2025-03-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12115144B2 (en) 2016-07-22 2024-10-15 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12115145B2 (en) 2016-07-22 2024-10-15 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12128021B1 (en) 2016-07-22 2024-10-29 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12138239B2 (en) 2016-07-22 2024-11-12 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12144793B2 (en) 2016-07-22 2024-11-19 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12239625B2 (en) 2016-07-22 2025-03-04 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12226389B2 (en) 2016-07-22 2025-02-18 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186298B2 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12226388B2 (en) 2016-07-22 2025-02-18 Flamel Ireland Limited Modified release gamma- hydroxybutyrate formulations having improved pharmacokinetics
US12167991B2 (en) 2019-03-01 2024-12-17 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US12226377B2 (en) 2019-03-01 2025-02-18 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US12167992B2 (en) 2019-03-01 2024-12-17 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11400065B2 (en) 2019-03-01 2022-08-02 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US12303478B2 (en) 2019-03-01 2025-05-20 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US12295926B1 (en) 2022-02-07 2025-05-13 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Also Published As

Publication number Publication date
ITMI971613A0 (en, 2012) 1997-07-07
IT1293583B1 (it) 1999-03-08
ITMI971613A1 (it) 1999-01-07

Similar Documents

Publication Publication Date Title
Chiodo et al. Possible mechanisms by which repeated clozapine administration differentially affects the activity of two subpopulations of midbrain dopamine neurons
Nitta et al. Continuous infusion of β-amyloid protein into the rat cerebral ventricle induces learning impairment and neuronal and morphological degeneration
Godar Light and death: photons and apoptosis
JP2003527320A (ja) 注意不足機能亢進障害および多発性硬化症疲労の治療のためのモダフィニルを含む組成物
JP2008546842A (ja) 酸化セリウムナノ粒子の抗炎症性、放射線防護性および寿命促進能
EP2464229B1 (en) Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with multiple sclerosis
Chiodo et al. Population response of midbrain dopaminergic neurons to neuroleptics: further studies on time course and nondopaminergic neuronal influences
CA2217902A1 (en) Use of gammahydroxybutyrric acid for the treatment of demential syndromes
CA2387486A1 (en) Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders
KR100425045B1 (ko) 약물중독의치료를위한멜라토닌함유약학적조성물
DE60315258T2 (de) Behandlung von nicht-schmerzhaften blasenstörungen mit modulatoren der alpha-2-delta-untereinheit des calciumkanals
Satoyoshi Therapeutic trials on progressive muscular dystrophy
Kössi et al. Effects of hexose sugars: glucose, fructose, galactose and mannose on wound healing in the rat
Nabeshima et al. Oral administration of NGF synthesis stimulators recovers reduced brain NGF content in aged rats and cognitive dysfunction in basal-forebrain-lesioned rats
EP0305181B1 (en) Ethyl-(+)-apovincaminate for treating demyelinization clinical patterns of autoimmune origin
DE3750464T2 (de) Pharmazeutisches Präparat zur Behandlung des Katarakts.
DE69511453T2 (de) Verwendung einer Kombination von Antineoplastonen zur Herstellung eines Arzneimittels zur Behandlung der Neurofibromatose
Lapierre et al. Comparison of chlormethiazole (Heminevrin) and chlordiazepoxide (Librium) in the treatment of acute alcohol withdrawal
RU2089234C1 (ru) Способ лечения воспалительных заболеваний гепатопанкреатодуоденальной зоны
US9649337B2 (en) Cerium oxide nanoparticles for the treatment and prevention of stroke and cardiovascular disease
GB2595077A (en) Combination of gaboxadol and lithium for the treatment of psychiatric disorders
EP0344158B1 (de) Schmerzpräparat
AU612140B2 (en) Prevention or interruption of panic states with an imidazobenzodiazepine
Baluchnejadmojarad et al. Inhibitory effect of high dose of the flavonoid quercetin on amygdala electrical kindling in rats
US6573265B2 (en) Use of 1-(aminoalkyl)-3-quinoxaline-2-on derivatives for the preparation of compounds having an antioxidant action

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead